Drug Shortage Report for TOBRAMYCIN FOR INJECTION
| Report ID | 266245 |
| Drug Identification Number | 00533688 |
| Brand name | TOBRAMYCIN FOR INJECTION |
| Common or Proper name | TOBRAMYCIN FOR INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | TOBRAMYCIN |
| Strength(s) | 1.2G |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1.2 g |
| ATC code | J01GB |
| ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2025-08-29 |
| Estimated end date | 2025-09-26 |
| Actual end date | 2025-09-26 |
| Shortage status | Resolved |
| Updated date | 2025-09-27 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a delay in release, we will be encountering a supply interruption on our Tobramycin for Injection, USP 1.2 g Vial effective August 29, 2025, until September 26, 2025. During this time, our Tobramycin Injection, USP 40 mg/mL products are available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2025-09-27 | English | Compare |
| v7 | 2025-09-26 | French | Compare |
| v6 | 2025-09-26 | English | Compare |
| v5 | 2025-09-23 | French | Compare |
| v4 | 2025-09-23 | English | Compare |
| v3 | 2025-08-30 | English | Compare |
| v2 | 2025-08-29 | French | Compare |
| v1 | 2025-08-29 | English | Compare |
Showing 1 to 8 of 8